Essack S Y
School of Pharmacy and Pharmacology, University of Durban-Westville, South Africa.
Pharm Res. 2001 Oct;18(10):1391-9. doi: 10.1023/a:1012272403776.
beta-Lactam antibiotics, viz., penicillin, penicillin derivatives, cephalosporins, cephamycins, carbapenems, monobactams. and monocarbams, are the most widely used of all antimicrobial classes by virtue of their high efficacy and specificity and the availability of several derivatives. The expression of one or several beta-lactamases (beta-lactam antibiotic-inactivating enzymes) represents the most widespread and the most clinically relevant resistance mechanism to these antibiotics. The development of beta-lactam antibiotics has thus been a continuous battle of the design of new compounds to withstand inactivation by the ever-increasing diversity of beta-lactamases. This article traces antibiotic development in response to the evolution of beta-lactamases.
β-内酰胺类抗生素,即青霉素、青霉素衍生物、头孢菌素、头霉素、碳青霉烯类、单环β-内酰胺类和单碳青霉烯类,由于其高效性、特异性以及多种衍生物的可得性,是所有抗菌类别中使用最广泛的。一种或几种β-内酰胺酶(β-内酰胺抗生素失活酶)的表达是对这些抗生素最广泛且临床上最相关的耐药机制。因此,β-内酰胺类抗生素的研发一直是一场持续的战斗,即设计新化合物以抵御不断增加的各种β-内酰胺酶导致的失活。本文追溯了针对β-内酰胺酶演变的抗生素研发历程。